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Heart failure (HF) is a costly, challenging and highly prevalent medical condition.
Hospitalization for acute decompensation is associated with high morbidity and mortality.
Despite application of evidence-based medical therapies and technologies, HF remains
a formidable challenge for virtually all healthcare systems. Repeat hospitalizations for
acute decompensated HF (ADHF) can have major financial impact on institutions
and resources. Early and accurate identification of impending ADHF is of paramount
importance yet there is limited high quality evidence or infrastructure to guide
management in the outpatient setting. Historically, ADHF was identified by physical exam
findings or invasive hemodynamic monitoring during a hospital admission; however,
advances in medical microelectronics and the advent of device-based diagnostics have
enabled long-term ambulatory monitoring of HF patients in the outpatient setting. These
monitors have evolved from piggybacking on cardiac implantable electrophysiologic
devices to standalone implantable hemodynamic monitors that transduce left atrial or
pulmonary artery pressures as surrogate measures of left ventricular filling pressure.
As technology evolves, devices will likely continue to miniaturize while their capabilities
grow. An important, persistent challenge that remains is developing systems to
translate the large volumes of real-time data, particularly data trends, into actionable
information that leads to appropriate, safe and timely interventions without overwhelming
outpatient cardiology and general medical practices. Future directions for implantable
hemodynamic monitors beyond their utility in heart failure may include management of
other major chronic diseases such as pulmonary hypertension, end stage renal disease
and portal hypertension.
Keywords: heart failure, implantable hemodynamic monitor, thoracic impedance, left atrial pressure monitor,
pulmonary artery pressure monitor, LAPTOP trial, CHAMPION trial
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Introduction

other ethical issues (Abraham et al., 2014). This review focuses
on implantable hemodynamic monitors that evolved from
electrophysiologic (EP) devices with extended functionality
to dedicated standalone pulmonary artery pressure monitors
(e.g., CardioMEMS )2 for guiding medical management
of hemodynamic and volume status in outpatients, with
demonstrable eﬀects on reducing hospital readmission.

Cardiovascular disease remains the leading cause of death in the
United States and worldwide (Lim et al., 2012; Santulli, 2013).
Heart failure (HF) is a costly, challenging and highly prevalent
medical condition with major public health concerns given the
associated signiﬁcant morbidity and mortality (Ramani et al.,
2010). Hospitalization for acute decompensated heart failure
(ADHF) is a sentinel event that signiﬁes disease progression and
an inability of the heart to maintain adequate hemodynamics
for perfusion and function of vital organs. Nearly half of these
patients are readmitted within 6 months (Jong et al., 2002)
and/or deceased by 1 year (Adams et al., 2005). The lifetime
risk of developing HF for Americans age 40 years or older is
approximately 20% (Yancy et al., 2013) The incidence of new
HF cases exceeds 650,000 annually (Yancy et al., 2013). Over one
million hospitalizations are attributed to HF annually with an
estimated cost of ∼$20 billion for the United States health care
system (Yancy et al., 2013; Sharma et al., 2015).
To contain costs and standardize management of patients
hospitalized for ADHF, the Centers for Medicare and Medicaid
Services have recently introduced regulations to withhold
or reduce payments for unnecessary hospitalizations for HF
(http://CMS.gov)1 . Increasingly scrutinized are readmission rates
and other performance metrics (e.g., length of hospital stay,
medical regimen at discharge) that are fuelling eﬀorts to
reduce HF readmissions. Evidence based therapies, including
optimal medical therapy with neurohormonal antagonists and
implantable devices (e.g., cardiac resynchronization therapy,
deﬁbrillators), are well outlined by major cardiovascular and
electrophysiological societies including the American College of
Cardiology, American Heart Association, Heart Failure Society
of America, European Society of Cardiology, European Heart
Rhythm Association, and Heart Rhythm Society (Heart Failure
Society of America et al., 2010; McMurray et al., 2012; Brignole
et al., 2013; Russo et al., 2013; Yancy et al., 2013; Kusumoto et al.,
2014). Despite application of these treatments and technologies,
HF remains a formidable challenge for virtually all healthcare
systems. Moreover, the quality of evidence for care, support and
monitoring systems as well as the infrastructure to support HF
patients, particularly in the outpatient setting, are lacking (Yancy
et al., 2013).
The recent development and clinical trials of implantable
hemodynamic monitoring devices hold promise to reduce HF
hospitalizations, with the potential to improve patient outcomes.
The limited but emerging supportive evidence is encouraging
further eﬀorts to improve the patient experience with this
clinically challenging medical condition. Leading experts in this
ﬁeld have acknowledged the diﬃculty of conducting clinical
trials using cardiac monitoring embedded with therapeutic
management to eﬀect “hard” clinical outcomes and endpoints
(Abraham et al., 2014). They have also underscored the
importance of careful clinical trial design, endpoint selection,
outcome assessment, management of actionable results, and

™

Historical Background
Early and accurate identiﬁcation of impending and active ADHF
is of paramount importance. Daily weight monitoring is a
low-cost, easily accessible method of monitoring HF patients
both in and out of the hospital. Unfortunately, weight as a
reference value is easily confounded by changes in diet and
muscle mass that are not related to intravascular volume status
or ﬁlling pressures (Wolfel, 2007) and previous studies have
found that the estimated positive predictive value for these
ﬁndings are generally poor (Lewin et al., 2005; Zhang et al., 2009;
Abraham et al., 2011a,b). Furthermore, while telemonitoring and
collaborative multidisciplinary outpatient care teams appear to
be practical eﬀective measures to improve the management of
HF, randomized studies have yet to conﬁrm this (Chaudhry
et al., 2010; Bekelman et al., 2015). The clinical symptoms
of dyspnea, orthopnea, weight gain, and leg edema are often
late indicators of congestion and volume overload that may
already warrant hospitalization. Physical examination maneuvers
such as inspection of the jugular venous pressure waveform,
hepatojugular reﬂux and the square wave sign are useful
surrogate measures of cardiac ﬁlling pressures, however, interand intra-observer variability, inconsistent manifestations, and
the need for the patient to present for a physical examination,
limit their applicability to identify early decompensated heart
failure in the outpatient setting (Drazner et al., 1999, 2008).
In addition, the sensitivity and speciﬁcity of these signs
and symptoms vary widely, depending on the clinical study
(Stevenson and Perloﬀ, 1989; McCullough et al., 2002).
A gold standard measure of congestion in HF is not overall
volume status (Verbrugge et al., 2014), but rather the pulmonary
artery occlusion pressure, also known as the pulmonary capillary
wedge pressure (PCWP). The PCWP reﬂects left sided cardiac
ﬁlling pressures and is measured by a pressure transducer on the
end of a pulmonary artery catheter. An inﬂatable balloon on the
distal portion of the catheter allows placement of the catheter
into a sub-selected pulmonary artery (PA) branch. An elevated
PCWP, exceeding 18–22 mmHg, indicates pulmonary edema and
congestion. Given the potential dangers of an indwelling PA
catheter for invasive hemodynamic monitoring, the patient is by
convention required to stay in the intensive care unit.
Advancement in medical microelectronics and the advent
of device-based diagnostics have been developed to enable
monitoring of ambulatory HF patients (Table 1). These devices
transmit and report objective, quantitative data via remote
monitoring systems. The premise of monitoring physiologic

1 CMS.gov.

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Ac
uteInpatientPPS/Readmissions-Reduction-Program.html. Last accessed May 14,
2015.
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Systolic, diastolic, and
mean pulmonary artery
pressure

Approved May 28, 2014

Ambulatory HF surveillance

Ambulatory surveillance in
HF patients with NYHA III
symptoms who have
preserved EF or reduced EF
on OMT, who have had a
HF hospitalization in the
previous year

HeartPod® (St Jude Medical,
Inc., USA)

CardioMEMS HF System
(CardioMEMS, Inc./St Jude
Medical, Inc., USA)

3

Not approved

RV systolic pressure,
RV diastolic pressure
(an estimate of PADP),
maximum change in
pressure over time
(dP/dt and –dP/dt)

Patients unable to perform Valsalva maneuvers and maintain
an airway pressure >39 mmHg for 8 s (required for periodic
device calibration)
Based on CHAMPION trial criteria, patient should not have
any of the following:
History of recurrent (>1) pulmonary embolism or deep vein
thrombosis
Inability to tolerate a right heart catheterization
Recent major cardiovascular event (e.g., myocardial
infarction, stroke) within 2 months of screening visit
Recent CRT implanted ≤3 months prior to enrollment
eGFR <25 ml/min who are non-responsive to diuretic therapy
or who are on chronic renal dialysis
High likelihood of undergoing heart transplantation within 6
months of screening visit
Congenital heart disease or mechanical right heart valve(s)
Known coagulation disorders
Hypersensitivity or allergy to aspirin, and/or clopidogrel

Left pulmonary artery
(ideally, basal segmental
branch)

Patients without an indication for ICD therapy or limited
thoracic venous access

Patients without an indication for ICD therapy or limited
thoracic venous access

Pertinent contraindications or restrictions

Left atrium

Right ventricle

Pectoral muscle region

Implant Location

CRT, cardiac resynchronization therapy; dP/dT, rate of rise of left ventricular pressure (mmHg/sec); EF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator;
NYHA, New York Heart Association functional class; OMT, optimal medical therapy; PADP, pulmonary artery diastolic pressure; RV, right ventricle.

™

Mean left atrial pressure

Not approved

Ambulatory HF surveillance
in patients who also meet
indication for ICD therapy

Intrathoracic
impedance and heart
rate variability

Chronicle® ICD and Chronicle®
implantable hemodynamic
monitor (Medtronic, Inc., USA)

Approved Nov 2004

Ambulatory HF surveillance
in patients who also meet
indication for ICD therapy

Primary measured
variable(s)

OptiVol® Fluid Status Monitoring
system (Medtronic, Inc., USA)

FDA Status

Primary Indication

Device

TABLE 1 | Device specifications and indications for use.
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parameters is to enable clinicians to use these surrogate
markers to optimize the patients’ medical therapy in the
ambulatory setting, before the onset of acute hemodynamic
decompensation. This concept of remote device monitoring is
also referred to as telemonitoring (Sousa et al., 2014). Several of
the currently available telemonitoring systems measure various
cardiac pressures and tailoring of medical therapy based upon
these pressures is therefore called “pressure guided therapy.”
The basis of pressure guided therapy involves the observation
that most patients with HF require hospitalization because of
excessive ﬂuid accumulation. Accumulation of ﬂuid occurs over
several weeks and eventually reaches a “threshold” that requires
hospitalization (Zile et al., 2008). Knowledge of these pressure
increases can thus allow adjustment of medications to avoid
reaching this “threshold” (Figure 1).
Early investigational, implantable heart function monitoring
devices piggybacked on the existing implantable cardioverter
deﬁbrillator (ICD) technology which had already established the
safety of right ventricular pacing leads and was being used in
the target population. Early devices used innovative transvenous
lead technology to provide mixed venous oxygen saturation and
pressures in the right ventricle (RV) (Ohlsson et al., 1996, 1998).
The correlation between RV end diastolic pressure and PA end
diastolic pressure was demonstrated. In addition, these devices
also could measure additional physiologic parameters such as
heart rate variability, body temperature, and other surrogates
of patient activity levels (Raina et al., 2015). Information
management varied and early models initially only provided realtime data during interrogations in the oﬃce. Later designs gained
the capacity to store data and to transfer it securely and remotely.
R
These devices culminated in the development of the Chronicle
IHM (IHM-2; Model 9520) (Figure 2A). The IHM-1 and IHM-2
devices have demonstrated signiﬁcant changes in RV pressures
associated with changes in diuretic therapy (Braunschweig et al.,
2002), β-adrenergic receptor blockers (Ishikawa et al., 2009),
biventricular pacing (Bruns et al., 2005), and inhaled therapies
for pulmonary hypertension patients (Fruhwald et al., 2003;
Karamanoglu et al., 2007).
Intrathoracic impedance monitoring was also evaluated as an
adjunct to monitoring heart failure patients with an indication
for an ICD or cardiac resynchronization therapy deﬁbrillator
(CRT-D) (Braunschweig et al., 2004; Yu et al., 2005). The
R
OptiVol
function, an exclusive technology of Medtronic
(Minneapolis, MN, USA) received the United States Food and
Drug Administration (FDA) approval in 20043 . ICD devices
with OptiVol can longitudinally monitor the conductance of
a microelectrical current between the RV deﬁbrillating coil
and device case. When the ﬂuid index sharply rises above the
baseline in conjunction with a decrease in thoracic impedance,
intrathoracic ﬂuid accumulation such as pulmonary congestion
is suggested. Elevated left ventricular (LV) ﬁlling pressure is
associated with increased intrathoracic ﬂuid (i.e., lung water),
which in turn is associated with increased conductance and

FIGURE 1 | (A) Pulmonary artery (PA) pressures rise over time and cross a
“threshold”; this results in decompensated heart failure and hospitalization. (B)
When the rise in PA pressure is identified and additional diuretic therapy is
given, the threshold is not crossed and hospitalization is avoided.

decreased impedance as this current travels across lung tissue.
Other concomitant device data including heart rate variability,
resting night heart rate, patient activity level, and the burden of
atrial tachycardia or ﬁbrillation noted around the time of changes
in Optivol ﬂuid index and thoracic impedance trends may help
to improve conﬁdence in interpretation of potentially actionable
data. Initial trials demonstrated increased sensitivity for early
detection of HF exacerbations with decreased unexplained
alarms in comparison to the traditional weight based monitoring
protocol (Abraham et al., 2011b).
Ambulatory monitoring of intrathoracic impedance has
not had the clinical impact that was initially anticipated, with
statistically non-signiﬁcant results from several contemporary
trials (Conraads et al., 2011; Yang et al., 2013) Contributing
factors likely include the diﬃculty determining the diﬀerence
between appropriate detection of pre-clinical events and false
alarms, as well as the need for third party involvements to
monitor trends and eﬀect appropriate therapeutic changes.
Threshold changes in impedance can also occur from noncardiac etiologies (e.g., pneumonia, pneumothorax, positive
pressure ventilation), pointing to the importance of interpreting
those data in association with other concomitant device data,
as well as clinical data from a (phone) discussion with the
patient. Furthermore, monitoring of electrophysiology (EP)
devices is traditionally far removed from those empowered to
make changes in a patient’s HF medications and arrange for
appropriate follow up. A recent retrospective review of the
data from the Fluid Accumulation Status Trial (FAST) and
Program to Access and Review Trending Information and
Evaluate Correlation to Symptoms in Patients With Heart
Failure (PARTNERS-HF) trials by Abraham and colleagues
suggested a novel scheme to stratify patients at risk for a HF

3 U.S.

Food and Drug Administration announcement, recently-approved devices.
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceAppr
ovalsandClearances/Recently-ApprovedDevices/ucm400550.htm. Last accessed:
March 30, 2015.
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FIGURE 2 | Implantable ambulatory heart failure hemodynamic monitors. (A) Chronicle® : (top left to bottom right) Implantable RV lead and ICD; lateral and
posterior-anterior chest radiographs after device placement. (B) HeartPOD® . Implantable left atrial device and distal anchor. (C) CardioMEMSTM HF System:
(i) pulmonary artery (PA) sensor; (ii) delivery catheter with preloaded PA sensor; (iii) pulmonary arteriograms showing a radiopaque PA sensor in a segmental branch of
the left pulmonary artery (PA) before (left) and after (right) contrast dye injection; (iv) patient electronics system for transmission of data. All images were adapted with
permission from Medtronic, Inc., St. Jude Medical, Inc., and Elsevier Inc.

published in 2011 and reported the safety, feasibility, accuracy,
and reliability of LAP monitoring (Troughton et al., 2011).
The Left Atrial Pressure Monitoring to Optimize Heart Failure
Therapy Study (LAPTOP-HF) trial was designed to determine
the safety and clinical eﬀectiveness of a physician-directed,
patient self-management therapeutic strategy, and has recently
been completed; results are eagerly awaited (Maurer et al., 2015).
Monitoring of PAP has been used for decades by cardiologists
to detect early signs of HF in the intensive care setting
(Rutherford et al., 1971). For ambulatory PAP monitoring,
CardioMEMS (St. Jude Medical Inc, Sylmar, CA) was developed
to directly measure systolic, diastolic and mean PAPs using
a miniaturized wireless electromechanical sensor implanted in
conjunction with a right heart catheterization procedure via
transvenous access (Figure 1C). As the sole FDA-approved
standalone device for outpatient HF monitoring, CardioMEMS
was tested and proven to signiﬁcantly reduce admissions for
patients with New York Heart Association functional class III HF,
regardless of left ventricular ejection fraction (LVEF) (Abraham
et al., 2011a; Adamson et al., 2014), even in those with HF with
preserved LVEF as opposed to those with reduced LVEF. A large
post-approval trial is already recruiting (goal N = 1200) to
verify the robustness, safety and usefulness of CardioMEMS in
the complex real-world setting, particularly in reducing the rate

related hospitalization using diagnostic physiologic monitoring
parameters germane to most modern ICD devices (Sharma et al.,
2015). Increasing numbers of device observations correlated
with an increased risk of a HF hospitalization. However, as
demonstrated in prior studies, rates of HF hospitalizations
associated with alerts were low, around 14% for ≤3
observations.
In contrast to prior eﬀorts that combined HF monitoring
therapies with therapeutic EP devices, the left atrial pressure
(LAP), and pulmonary artery pressure (PAP) ambulatory heart
failure monitoring implantable devices were developed as purely
diagnostic devices (Figures 2B,C). LAP monitoring was being
explored around the same time that intrathoracic impedance
was in the early post-marketing surveillance period (Ritzema
et al., 2007). The LAP monitoring device incorporates direct
left atrial pressure monitoring via a pressure transducer secured
to the interatrial septum. Transvenous access and a transseptal
puncture are required for implantation (see Table 2). Similar to
R
early EP devices, LAP monitors (HeartPOD
, St. Jude Medical
Inc, Sylmar, CA, USA) can transfer data through radiofrequency
wireless transmissions done by direct interrogation of the coil
R
antenna using the handheld patient advisory module (PAM
)
(Figure 1B). The Hemodynamically Guided Home Self-Therapy
in Severe Heart Failure Patients (HOMEOSTASIS) trial was

Frontiers in Physiology | www.frontiersin.org
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TABLE 2 | Procedural characteristics.
LAP monitor

PAP monitor

™

Device

HeartPOD®

CardioMEMS

Access

Venous (femoral and subclavian vein)

Venous (usually femoral)

Approach

Transseptal puncture

Via PA

Accessories

Brockenbrough needle through 8 Fr sheath, 11 Fr delivery
sheath in LA

12 Fr introducer sheath, dilators with access guidewire,
110-cm PA catheter, 0.018 x 260–300 cm fixed core
guidewire with straight or angled tip

Intraprocedural anticoagulation

Heparin 5000 IU, intravenous

None

Imaging

Fluoroscopy, echocardiography (including TEE, TTE, ICE)

Fluoroscopy, pulmonary arteriography

Method and location of sensor deployment

Cinching and fixation of device anchors to inter-atrial
septum

Release of preloaded sensor from over-the-wire delivery
catheter

Associated implantable components

Coil antenna and lead

None

Duration of procedure

>1 h

20 min

Device interrogation

Transcutaneous detection of implanted sensor
lead-antenna coil signal using handheld patient advisory
module (PAM)

Transcutaneous detection of sensor-released energy in
response to radiofrequency pulse from patient
electronics unit

Post-procedural antithrombotics

Aspirin and warfarin for 30 days, then aspirin indefinitely

Aspirin and P2Y12 inhibitor (clopidogrel) for 1 month,
then aspirin indefinitely; warfarin may substitute for
aspirin after the first month if chronic anticoagulation
therapy is required

Duration of implantation

Lifelong

Lifelong

Fr, French gauge; IU, international units; LA, left atrium; PA, pulmonary artery; ICE, intracardiac echocardiography; TEE, transesophageal echocardiography; TTE, transthoracic
echocardiography.

and a delivery sheath is placed to allow for placement of the
sensor lead and LA sensor. Once the correct position is conﬁrmed
with intracardiac or transesophageal echocardiography, the LA
sensor with the implantable sensor lead is deployed. The sensor
is oriented to the LA and is buttressed and immobilized
permanently with proximal and distal nitinol anchors on the
respective right and left atrial sides of the interatrial septum upon
deployment. The electrode is then transferred from the femoral
location to the infraclavicular position via an exchange catheter
and attached to communication module. The metal alloy can,
referred to as the implantable communications module or ICM,
containing the coil antenna and microelectronics is implanted
in the same manner as for a pacemaker. A prospective openlabel observational study of 84 patients found that freedom from
device failure was 95% at 2 years and 88% at 4 years (Troughton
et al., 2011).
CardioMEMS is a battery-free, leadless sensor (15 mm ×
3 mm) consisting of a coil and capacitor encased in silicone, with
a nitinol wire loop at each end of the sensor (Figure 2Ci). The
CardioMEMS device is preloaded on a delivery catheter with
a tether release system (Figure 2Cii). The design of the system
is based on microelectromechanical principles of resonance
whereby an external antenna wand emitting radiofrequency
energy can cause varying degrees of oscillations in the sensor
depending on the ambient pressure. The implanting procedure
requires a transfemoral venous approach for accommodation
of a 12-French introducer sheath for the CardioMEMS delivery
catheter (Table 2). PA catheterization is performed to document
right sided pressures before and after device implantation. After
identifying a posterior segmental branch of the left PA by
selective pulmonary arteriography (Figure 2Ciii), the sensor is

of HF hospital readmissions and in improving patients’ quality of
life (clinicaltrials.gov).

Deployment and Monitoring
The Chronicle features a programmable device that bears
resemblance to a pacemaker pulse generator, which is implanted
to process and store information from the pressure sensor near
the tip of the transvenous lead (Bourge et al., 2008). The device
continuously records data such as heart rate, body temperature,
estimated patient activity level, RV systolic and diastolic pressure,
RV pressure changes, and estimated PA diastolic pressure.
It is only programmed to store a smaller dataset based on
programmed intervals, recording the median 6th and 94th
percentile levels over that period. In the COMPASS-HF trial,
patients were asked to use a handheld radio frequency device
to transmit readings at least once weekly using a telephone line.
Information was stored on a secure server that clinicians could
access through a secure web site.
The device characteristics and key aspects of deployment
of the HeartPOD and CardioMEMS are summarized in
Table 2. The HeartPOD system consists of a microelectronic
sensor and diaphragm housed in a cylindrical titanium casing
(approximately 3 mm × 7 mm) equipped with deployment
anchors, and linked with an implantable sensor lead and a coil
antenna within a can that resembles a pacemaker (Figure 1B).
After gaining femoral venous access, a Brockenbrough needle
and transseptal sheath are advanced, and puncture of the
interatrial septum is performed. Thereafter, a guidewire is
introduced via a subclavian vein to secure the transseptal location

Frontiers in Physiology | www.frontiersin.org
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secure website (https://cardiomemshf.com/user/sign_in) is
accessible to healthcare professionals to view the interrogated
data. The HeartPOD, CardioMEMS and other nonEP (i.e., without pacemaking or deﬁbrillator functions)
implantable monitoring systems have built-in, untapped
features including cardiac output, heart rate variability, and
electrocardiographic monitoring. If oﬃcially approved by
the FDA, these additional monitoring parameters will likely
improve characterization of hemodynamic derangements, and
potentially reduce false-positive results, and associated resource
utilization.
When using surrogate measures to direct therapy, it is crucial
to understand exactly what is being measured. While mean PAP
and LAP are both considered adequate surrogates for ﬁlling
pressures, they are two diﬀerent measurements and neither is
the gold standard measurement (LVEDP). The PCWP is often
considered to reﬂect left ventricular preload and pulmonary
capillary hydrostatic pressure, however, there is ongoing debate
about the validity of this assumption in the setting of various
conditions including chronic pulmonary disease, mechanical
ventilation and pulmonary venous scarring. In principal, the LAP
would be a more accurate measurement as it is physically and
physiologically closer to the gold standard, LVEDP, however it is
more invasive to measure. A brief literature review did not reveal
any studies comparing the three measurements simultaneously,
however there are a few studies comparing LAP and PCWP. In
1962, the PAP, PCWP, and LAP measurements of 11 patients
with either clinically normal hearts or suspected mitral valve
disease were studied with right heart catheterization in a control
state, during a norepinephrine infusion, and during positive and
negative intraalveolar pressures (Luchsinger et al., 1962). This
study demonstrated a strong linear relationship (r = 0.95)
between PCWP and LAP in all settings with the PCWP being
consistently 35% higher than the LAP. A more contemporary
study of lightly sedated dogs reported that the mean PCWP
accurately reﬂected LAP (Chaliki et al., 2002). In this study,
mean PCWP again was highly correlated with LAP (r = 0.99;
slope = 0.99; intercept = −0.46 mmHg). However, a study of 43
dogs and 30 patients in severe hemorrhagic, traumatic or septic
shock noted that a dangerous rise in PAP was not reﬂected by
PCWP or even central venous pressure (Hardaway, 1982). This
discrepancy was attributed to suspected partial obstruction of the
pulmonary microcirculation due to disseminated intravascular
coagulation in the pulmonary venules. Central venous pressure
should only rise due to high pulmonary pressures if there is RV
failure.
With IHM, it is not only the sites from which data are collected
but the manner in which they are recorded, stored and reported.
In the HOMEOSTASIS trial, subjects were requested to make
two LAP measurements a day with additional measurements
during symptoms (Troughton et al., 2011). In the CHAMPION
trial, continuous PAP measurements are recorded (Abraham
et al., 2011a). Clearly, there are tradeoﬀs between the challenge
of requiring patients in the real world to make multiple daily
recordings using a separate handheld device and voluminous
amounts of data that require no input from patients to
collect.

liberated as the tether release wire is pulled and withdrawn
while the nitinol loops uncoil from the delivery catheter to
maintain device position in the PA branch. Interrogation of PAP
requires the patient to be in a supine position with the supplied
pillow-like wand placed underneath the patient (Figure 2Civ).
After approximately 20 s, systolic, diastolic and mean PAPs are
measured and transmitted via wireless cellular network to the
CardioMEMS data center. In the landmark CardioMEMS Heart
Sensor Allows Monitoring of Pressure to Improve Outcomes in
NYHA Class III Heart Failure Patients (CHAMPION) trial, the
device- or system-related complication rate was only 1.4%, with
an overall pressure-sensor failure rate of 0% (Abraham et al.,
2011a).
Patients enrolled in the CHAMPION trial were asked to
make daily measurements of their PAPs using their portable
electronic unit and a special pillow containing an antenna to
take daily sensor readings which are transmitted through a
modem or cellphone to a secure patient database (Adamson
et al., 2011). By requesting patients to lay on the special pillow,
measurements should be more consistent reproducible and
ideally leveled. In the LAPTOP-HF trial, LAP, body temperature,
and intracardiac electrogram were measured. Subjects were able
to power and interrogate their devices with radiofrequency
wireless transmissions from their patient activator module or
PAM (Ritzema et al., 2007), with capacity to store up to 3 months’
data if 6 waveforms are acquired daily.
Both the HeartPOD and CardioMEMS systems use a
physician-guided self-management model that is intuitive
and conceptually sound. However, experts in the ﬁeld have
universally acknowledged the challenges in conducting
implantable monitoring trials to demonstrate impacts on clinical
outcomes, particularly with how the interrogated physiologic
data are handled (Abraham et al., 2014). Monitoring of device
data requires patient compliance, “physician compliance” and
a structured action plan or algorithm in order to execute a
successful program. Achieving the goal of reducing patient
hospitalization and readmission for HF requires a team eﬀort
involving the patient, caretaker, primary care physician,
cardiologist, nurse and/or support staﬀ. As a team, they
will need suﬃcient resources and training to appropriately
interpret data trends. Standard easy to use protocols would
lead to more uniform management and optimize the ability
to study IHMs. These protocols will need to have some
ﬂexibility so health care providers can customize treatment
plans to each individual as necessary. In monitoring data,
it has been emphasized that data trends are more crucial to
successful management than acting on individual abnormal
data points. Potential harm could also be introduced with
injudicious remote monitoring when treatments such as diuretic
therapy and vasodilators are administered without careful
consideration, understanding and interpretation of abnormal
data. Establishing a good line of communication with the
patient, and exercising clinical judgment (e.g., focused history
taking to gather clinical cues, scheduling an outpatient visit
when required, and assessing renal function and/or electrolytes
after adjustment of medical therapy such as diuretics), may
help to clarify abnormal and outlying data trends. An online
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Study population

Objective

Evaluate the
sensitivity and
unexplained
detection rate
associated with
changes in
intrathoracic
impedance and
with changes in
daily weight and to
compare the
performance of
these two
measures

Compare
unplanned
healthcare
evaluation for a
patient detected
audible device
alerts with or
without proof of
cardiac
decompensation

Evaluate predictive
ability of a monthly
review of HF
device diagnostic
data to identify
patients at higher
risk for HF
hospitalizations
within 30 days

N = 156, HFREF
NYHA I–III
symptoms with
successfully
implanted specific
Medtronic ICD or
CRT-D devices

N = 43; HFREF
with NYHA III–IV
on OMT
undergoing
Medtronic ICD or
CRT-D
implantation

N = 694, patients
with HF
undergoing CRT-D
implantation

Fluid accumulation
status trial
(Abraham et al.,
2011b)

OptiVol fluid index
predicts acute
decompensation
of heart failure with
a high rate of
unexplained
events (Yang et al.,
2013)

Program to access
and review
trending
information and
evaluate
correlation to
symptoms in
patients with heart
failure
(Partners-HF)
(Whellan et al.,
2010)

OPTIVOL: INTRATHORACIC IMPEDANCE MONITORING

Study (citation)
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8
• Primary
outcome:
occurrence of HF
related adverse
event.
• Secondary
outcome:
occurrence of HF
related healthcare
utilization,
occurrence of HF
related pulmonary
congestion event

Primary outcome:
signs and
symptoms of HF
on physical
examination and
serologic
evaluation

• Primary
outcome: number
of subjects with at
least 30 days of
daily impedance
measurements;
• Secondary
outcomes
included change in
thoracic
impedance
associated with
HF hospitalization
for an
exacerbation of HF
or outpatient HF;
number of adverse
events

Formal
outcomes

TABLE 3 | Available literature and clinical evidence on device efficacy.

Prospective
multi-center
observational
cohort study

Prospective
observational
single site study

Multicenter
non-randomized,
prospective,
double-blinded
investigation

Study design

Monthly review of
HF device
diagnostic data to
identify patients at
increased risk for
HF hospitalizations
within 30 days

OptiVol fluid index
had high sensitivity
and high
unexplained
detection rate

Increased
sensitivity and
decreased
unexplained
alarms in
comparison to
weight based
protocol

Key findings

™
™

™

, Marquis® DR,

• Meet ICD indications
• NYHA III or IV
• Receiving or have received
a Medtronic CRT ICD within
the previous 3 months
• Able to sign and date
informed consent
• 18 years of age or greater
• Available for follow-up
visits, and be willing and
able to comply with study
protocol

Consecutive patients at a
single center with HFREF
(≤35%) NYHA III–IV on OMT
for ≥3 months undergoing
implantation of either a
CRT-D (InSync Marquis
7298; Concerto C174AWK )
or an ICD (Virtuoso VR
D164VWC; Virtuoso DR
D164AWG) from Sep. 2010
to Oct. 2012

or InSync III Marquis
placed in the upper part of
the left or right side of their
chest
• Subjects with a lead that is
inserted through a vein and
placed in the RV (a
transvenous RV lead)
• Subjects who underwent
the ICD implant procedure,
or any readjusting of the
ICD, 30 days or more prior
to enrolling in the study

Marquis

• Subjects with one of the
following ICDs: InSync
Marquis , InSync II

Inclusion criteria

(Continued)

• Acute MI, CABG or PTCA /stent within the last
month
• Mechanical right heart valve
• Chronic (permanent) atrial arrhythmias
• Life expectancy of less than 12 months
• Status post-heart transplant
• Undergoing kidney dialysis
• Enrolled in a concurrent study that may confound
the results of the study

• Life expectancy of less than 1 year
• Anticipated difficulty in completing follow-up

• Enrolled in another clinical study
• Received a heart transplant
• Unable or unwilling to follow the study schedule of
visits

Exclusion criteria

Mooney et al.
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All-cause mortality
or hospitalization
for HF (time to first
event)

N = 325, patients
with NYHA II–IV HF

Diagnostic
outcome trial in
heart failure
DOT-HF (Van
Veldhuisen et al.,
2011)

• Primary
endpoint:
composite of
all-cause mortality
or heart failure
hospitalization.
• Secondary
endpoints:
all-cause mortality,
the impact on total
health care
utilization, quality
of life and cost
effectiveness

Formal
outcomes

9

CardioMEMS heart
sensor allows
monitoring of
pressure to
improve outcomes
in NYHA class III
heart failure
patients
(CHAMPION) trial
(Abraham et al.,
2011a)

N = 550, Patients
with NYHA III HF
with a HF
admission within
the past year,
patients with low
LVEF were on or
started on OMT
6-month HF
hospital admission
rate

• Primary
outcomes: rate of
HF
hospitalizations,
and freedom from
device failures
• Secondary
outcomes: change
from baseline in
mean PAP,
proportion of
patients
hospitalized for HF,
days alive outside
of the hospital,
quality of life

CARDIOMEMS: PULMONARY ARTERY PRESSURE MONITOR
Evaluate the
N = 12, NYHA
Correlation of PAP
Comparison of a
accuracy of a new
II–IV
between wireless
radiofrequencyHF sensor,
monitoring, PA
based wireless
catheterization and CardioMEMS, for
pressure sensor to
PAP monitoring
echocardiography
Swan-Ganz
compared with PA
at 0 and 60 days
catheter and
catheterization and
echocardiography
echocardiography
for ambulatory
in ambulatory HF
assessment of
patients at 0 and
pulmonary artery
60 days
pressure in heart
post-implantation
failure (Verdejo
et al., 2007)

Objective

Study population

Study (citation)

TABLE 3 | Continued

Prospective,
multicenter,
randomized,
single-blind clinical
trial

Single arm open
enrolment with
independent blind
operators
recording device
measure-ments

Randomized
open-label trial

Study design

Patients allocated
to the treatment
arm had a
significant
reduction in HF
related
hospitalizations (84
vs. 120, HR 0.72,
95% confidence
interval 0.60–0.65,
p = 0.0002) with a
NNT of 4 to
prevent one HF
hospitalization

Wireless PA
monitoring
correlated well with
PA catheter and
echocardiographic
measurements

Trial terminated
early owing to slow
enrolment and
technological
improvements;
post-hoc futility
analysis suggested
positive result
would have been
unlikely

Key findings
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• History of recurrent (>1) pulmonary embolism or
deep vein thrombosis
• Unable to tolerate a right heart catheterization
• Major cardiovascular event (e.g., MI, CVA) ≤2
months of screening visit
• CRT implanted ≤3 months prior to enrollment
• eGFR <25 ml/min who are non-responsive to
diuretic therapy or who are on chronic renal dialysis
• Likely to undergo heart transplantation ≤6 months
of screening visit
• Congenital heart disease or mechanical right heart
valve(s)
• Known coagulation disorders
• Hypersensitivity or allergy to aspirin, and/or
clopidogrel
• HF (HFpEF or HFrEF) ≥3
months
• NYHA III
• Subjects with HFrEF must
be receiving a β-blocker for
3 months and an ACE-I or
ARB for 1 month unless in
the investigator’s opinion,
the subject is intolerant to
β-blockers, ACE-I or ARB
• At least 1 HF
hospitalization ≤12 months
of screening visit
• PA branch diameter of
7–15 mm (implanted vessel)

(Continued)

• Recent ACS, CABG, or PTCA within last 3 months
• Mechanical right heart valves
Pulmonary or tricuspid stenosis
• Documented pulmonary embolism
• Pulmonary infarction within last 3 months
• Pregnant
• Active uncontrolled infection

• Post-heart transplant or actively listed on the
transplant list and reasonable probability of
undergoing transplantation in the next year
• Received a CABG or valve surgery in last 90 days
• MI in the last 40 days
• Life expectancy <1 year in the opinion of the
physician
• Severe COPD, as determined by physician and
documented in medical records
• Listed for valve replacement/valve repair
• Severe, primary pulmonary hypertension
• Serum creatinine ≥2.5 mg/dl measured within 14
days prior to enrolment
• Chronic renal dialysis
• Continuous or uninterrupted (≥2 stable infusions
per week) infusion (inotropic) therapy for HF
• Complex and uncorrected congenital heart disease

• HF NHYA II–IV
• LVEF ≤35%
• Indication for device
implant according to
ESC/AHA guidelines
• A HF hospitalization or ED
visit necessitating therapy
within the past 12 months

NYHA II–IV patients referred
for ADHF with normal
ventilation/perfusion lung
scan and normal tricuspid
regurgitation signal on
echocardiography

Exclusion criteria

Inclusion criteria

Mooney et al.
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6-month hospital
readmission rate

N = 119, NYHA III
patient with LVEF
≥40% enrolled in
CHAMPION trial

Wireless
pulmonary artery
pressure
monitoring guides
management to
reduce
decompensation
in HFpEF
(Adamson et al.,
2014)
6-month hospital
readmission rate

Formal
outcomes

The reducing
decompensation
events utilizing
intracardiac
pressures in
patients with
chronic heart
failure (REDUCEhf)
trial (Adamson
et al., 2007, 2011)

N = 400. NYHA
II–III patients with
an indication for
ICD and a previous
HF hospitalization

Primary efficacy
end point of HF
hospitalizations,
ED visits, or urgent
clinic visits

Primary outcome:
HF-related events
(defined as
hospitalizations
>24 h or
hospitalizations
<24 h requiring
intravenous HF
therapy, ED visits,
or urgent clinic
visits requiring IV
therapy for HF)
Primary safety end
point: freedom
from
system-related
complications at 6
months

CHRONICLE: RIGHT VENTRICULAR PRESSURE AND OXYGEN SATURATION

Objective

Study population

Study (citation)

TABLE 3 | Continued

Prospective,
randomized, single
blind (subject),
parallel-controlled
trial

Subgroup from a
prospective,
multicenter,
randomized,
single-blind clinical
trial

Study design

Trial and
enrollment
stopped early due
to lead failures in
previous trials

50% reduction in
hospitalization,
more changes in
diuretic and
vasodilator
therapies

Key findings

• At least 18 years old
• NYHA II or III
• Clinically accepted
indication for
• ICD therapy
• OMT
• for at least 3 months prior
to baseline
• evaluation
• At least one HF-related
• event within the
previous12 months

See CHAMPION trial

Inclusion criteria

10

(Continued)

• Existing implantable CRM device (except a
single-chamber ICD being considered for upgrade
to a Chronicle ICD)
• Indication for atrial pacing and/or CRT
• Severe COPD, severe restrictive airway diseases;
or primary pulmonary arteryhypertension
• Known ASD or VSD
Known tricuspid or pulmonary stenosis
• Mechanical or bioprosthetic right heart valves
• Severe, non-cardiac condition limiting 12-month
survival
• eGFR <30 mL/min/1.73 m2 or on chronic renal
dialysis
• Likely to undergo cardiac transplantation within 12
months of implant
• Receiving continuous or intermittent intravenous
doses of vasoactive agents and/or positive inotropic
therapy
• Females of childbearing age not using reliable
contraceptive measures

See CHAMPION trial

Exclusion criteria

Mooney et al.
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N = 8; patients
with NYHA III–IV
symptoms and at
least 1 HF
hospitalization or
unplanned visit for
parenteral therapy
in the last year

LAP correlation
with simultaneous
PCWP at 12
weeks

Primary end points
included failure,
and reduction in
the rate of
HF-related events
(hospitalizations
and emergency or
urgent care visits
requiring
intravenous
therapy), freedom
from
system-related
complications,
freedom from
pressure-sensor

N = 274, NHYA
III-IV patients with
an indication for
ICD; patients were
on OMT for at
least 3 months
and had a HF
hospitalization or
ED visit within the
preceding 3
months

Chronicle offers
management to
patients with
advanced signs
and symptoms of
heart failure
(COMPASS-HF)
(Bourge et al.,
2008)

Direct left atrial
pressure
monitoring in
ambulatory heart
failure patients:
initial experience
with a new
permanent
implantable device
(Ritzema et al.,
2007)

Objective

Study population

Study (citation)

TABLE 3 | Continued
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• Primary
outcome: LAP
correlation with
simultaneous
PCWP at 12
weeks
• Primary safety
end point: freedom
from system
complications

• Primary
outcome: efficacy
of designated
treatment
strategies by
demonstrating a
reduction in the
rate of all HF
events in the
treatment group
compared to the
control group
• Primary safety
end point:
freedom from
system-related
complications and
pressure sensor
failure at 6 months
• Secondary
outcome: health
care utilization,
survival and days
alive out of the
hospital, rate of
adverse events,
predictive value of
pressure change
in the control
group, quality of
life, NYHA class,
6-min walk test
performance

Formal
outcomes

Multicenter,
non-randomized,
open-label
feasibility clinical
trial (first human
experience with a
permanently
implantable, direct
LAP monitoring
system)

Prospective,
multicenter,
randomized,
single-blind
(subject),
parallel-controlled
trial

Study design

Ambulatory
monitoring of
direct LAP with a
new implantable
device was well
tolerated, feasible,
and accurate at a
short-term
follow-up

The Chronicle
group had a
non-significant
21% lower rate of
all HF-related
events compared
with the control
group (p = 0.33).
A retrospective
analysis of the
time to first HF
hospitalization
showed a 36%
reduction
(p = 0.03) in the
relative risk of a
HF-related
hospitalization in
the Chronicle
group

Key findings

• Established HF
• At least 1 HF
hospitalization or unplanned
visit for parenteral therapy in
the last year
• Ability to perform a
modified Valsalva maneuver
and achieve an airway
pressure >40 mm Hg with
an open glottis for >10 s

• NYHA III or IV
• Managed with standard
medical therapy for HF
(such as diuretic, ACE-I or
ARB, and β-blocker for at
least 3 months prior to the
baseline evaluation
• At least one HF-related
hospitalization or ED visit
requiring intravenous
treatment within 6 months
prior to baseline evaluation

Inclusion criteria

(Continued)

• Prior atrial septal surgery
• PFO >2 mm;
• Stroke or systemic thromboembolism within 6
months;
• Chronic AF;
• Atrial or ventricular thrombus;
• Gastrointestinal bleeding in the last 6 months;
• Requirement for chronic anticoagulation; or
intolerance to aspirin, clopidogrel, or ticlopidine

• Likely to be transplanted within 6 months from
randomization or will remain hospitalized until
transplantation
• Severe COPD or restrictive airway disease
• Continuous positive inotropic therapy
• Known ASD or VSD
• Mechanical right heart valves
• Stenotic tricuspid or pulmonary valves
• Presently implanted non-compatible pacemaker
or ICD
• CRT which has not achieved optimal
programming for >3 months
• Major cardiovascular event within 3 months prior
to baseline evaluation
• Severe non-cardiac condition limiting 6-month
survival
• Primary pulmonary artery hypertension
• Serum creatinine greater than or equal to
3.5 mg/dL or on chronic renal dialysis
• Enrolled in concurrent studies that may confound
the results of this study
• Pregnant or with child bearing potential and who
are not on a reliable form of birth control

Exclusion criteria

Mooney et al.
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Objective

LAP correlation
with simultaneous
PCWP at 3 and 12
months

Study population

N = 84 patients
with chronic
severe HF;
patients in phase 2
of enrollment had
AF (N = 44)

Study (citation)

Hemodynamically
guided home
self-therapy in
severe heart failure
patients
(HOMEOSTASIS)
trial (Troughton
et al., 2011)

TABLE 3 | Continued

Primary endpoints:
LAP correlation
with simultaneous
PCWP at 3 and 12
months; freedom
from Major
Adverse Cardiac
and Neurological
Events at 6 weeks

Formal
outcomes
Prospective,
multicenter,
observational
open-label registry

Study design

LAP was highly
correlated with
simultaneous
PCWP tracing; 82
out of 84 devices
successfully
implanted; 95%
freedom from
device failure

Key findings

• Age >18 and <85
• Documented history of HF
with systolic or diastolic
dysfunction of at least 6
months’ duration
• Patients with LVEF <40%
should receive maximally
tolerated doses of ACE-I (or
ARB if ACE-I is not
tolerated), β-blockers, and
anti-aldosterone therapy.
The combination of
hydralazine and nitrates
should be considered in the
persistently symptomatic
African American patient
• A history of NYHA II (OUS
only), III or IV symptoms
• Minimum of one (1) prior
hospital admission within
the last 12 months for
exacerbation of HF or one
(1) presentation to the ED or
clinic requiring parenteral
diuretic, vasodilator,
inotrope, nesiritide, or
equivalent treatment
• Female subjects of
childbearing potential must
have a negative pregnancy
test within seven (7) days
before the procedure
• Central venous vascular
access
• Capable of Valsalva
maneuver with airway
pressure >40 mm Hg for
10 s
• The subject and the
treating physician agree that
the subject will comply with
all required post-procedure
follow-up, and that the
patient is capable of correct
device use as outlined in the
protocol

Inclusion criteria

Frontiers in Physiology | www.frontiersin.org

12

(Continued)

• Intractable HF with resting symptoms despite
maximal medical therapy or active listing for cardiac
transplantation (<6 months’ survival expected)
• Resting SBP <90 or >180 mmHg
• Acute MI, unstable ischemic syndrome within the
last 6 weeks
• PCI or cardiac surgery performed or planned
within 6 weeks
• Coexisting stenotic valve lesions, vegetations,
hypertrophic cardiomyopathy, amyloidosis or other
infiltrative heart disease, constrictive, restrictive
disease, tamponade, or moderate or large
pericardial effusion
• History of deep venous thrombosis or pulmonary
embolism
• Surgical correction of congenital heart disease
involving atrial septum
• CVA or TIA within 6 months. History of
uncorrected cerebral vascular disease
• Atrial or ventricular thrombus, tumor or systemic
thromboembolism
• Symptomatic bradyarrhythmia or sustained VT/VF
unless successfully treated with CRM device for 6
weeks
• ASD or PFO >2 mm in diameter

Exclusion criteria

Mooney et al.
LAP and PAP monitors

October 2015 | Volume 6 | Article 271

Objective

Safety and clinical
effectiveness of a
physician-directed,
patient
self-management
therapeutic
strategy based on
LAP measured
twice daily by a
standalone
implantable sensor
or CRT-D
compatible sensor,
compared with a
control group
receiving OMT

Study population

Plan for N = 730
patients with
NYHA III
symptoms and a
HF hospitalization
for elevated BNP
within the last year

Study (citation)

Left atrial pressure
monitoring to
optimize heart
failure therapy
(LAPTOP-HF)
(Maurer et al.,
2015)

TABLE 3 | Continued
Study design

Prospective,
multicenter,
randomized,
controlled clinical
trial

Formal
outcomes

• Primary
outcome:
reduction in
relative risk of HF
hospitalization
• Primary safety
end point: freedom
from system
complications at
12 months

Frontiers in Physiology | www.frontiersin.org
Ongoing, not
recruiting
participants

Key findings

• Have ischemic or
non-ischemic
cardiomyopathy with either a
history of reduced or
preserved LVEF and HF for
at least 6 months
• NYHA III documented at
screening visit
• Be receiving appropriate
medical therapy for HF as
per ACC/AHA guidelines for
at least 3 months prior to the
randomization visit
• Minimum of one (1) prior
hospital admission within the
last 12 months for acute
exacerbation of HF of at
least one (1) calendar date
change duration requiring
intravenous or invasive HF
therapy. If CRT device
previously implanted, the HF
hospitalization must be ≥30
days after CRT implantation.
Alternatively, if patients have
not had a heart failure
hospitalization within the
prior 12 months, they must
have an elevated BNP level
of at least 400 pg/ml or an
N-terminal pro-BNP
(NT-proBNP) level of at least
1,500 pg/ml, according to
local measurement at the

Inclusion criteria
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(Continued)

• Age <18 years
• Pregnant
• Intractable HF with resting symptoms despite
maximal medical therapy
• Patients listed for cardiac transplantation who are
not likely to be transplanted within 12 months and
who have improved to NYHA III without outpatient
intravenous vasoactive medications or a VAD are
eligible for the study, if they meet the other
inclusion/exclusion criteria
• Resting SBP <80 or >180 mmHg
• Acute MI, ACS, PCI, new CRM device (pacemaker,
ICD, and CRT), CRM system revision, lead extraction
or cardiac or other major surgery within 40 days
• Coexisting, untreated, hemodynamically severe
stenotic valve lesions, vegetations, hypertrophic
cardiomyopathy with significant resting or provoked
subaortic gradient, acute myocarditis, tamponade,
or large pericardial effusion
• ASD or PFO (with more than trace shunting on
color Doppler or intravenous bubble study) or
surgical correction of significant congenital heart
disease involving atrial septum such as PFO or ASD
closure device
• CVA or TIA within 6 months
• Inadequate vascular access for device implantation
• 2D echocardiographic evidence of, or history of,
unresolved left atrial or ventricular thrombus
• Recent (within 6 months) or persistent deep
venous thrombosis, pulmonary or systemic
thromboembolism
• Life expectancy < 1 year due to another illness
• Coagulopathy or uninterruptible anticoagulation

• Life expectancy <1 year from malignancy, primary
pulmonary hypertension, renal, hepatic, or
neurological condition, etc
• Gastrointestinal bleeding during the last 6 months
• Coagulopathy or uninterruptible anticoagulation
therapy or unable to take antiplatelet medications
• Creatinine >2.5 gm/dl
• Temperature >37.8oC or WBC >13,000/mm3
• Currently participating in an investigational drug or
another device study that has not completed the
primary endpoint or that clinically interferes with the
current study endpoints

Exclusion criteria

Mooney et al.
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Study population

Objective

Formal
outcomes

Study design

Key findings

Exclusion criteria

therapy or contraindication for all of the forms of
antiplatelet/anticoagulant treatments anticipated in
the protocol
• eGFR < 30 ml/min/1.73 m2 by the MDRD method
• Liver function test > 3 times upper limit of normal
• Severe pulmonary disease producing frequent
hospitalizations for respiratory distress and requiring
continuous home oxygen
• Pulmonary hypertension with a PASP ≥
80 mm/Hg on screening echocardiogram
• Active infection requiring systemic antibiotics
• History of active drug addiction, active alcohol
abuse, or psychiatric hospital admission for
psychosis within the prior 2 years
• Currently participating in a clinical investigation
that includes an active treatment arm
• Unable to demonstrate understanding and
capability of using the patient advisory module, or
PAM, appropriately
• Does not have access to a telephone line usable
for remote Patient Activator Module follow-up or
electrical outlet for recharging the Module

Inclusion criteria

time of screening (within 30
days of the screening
visit/consent)
Provide informed consent
for study participation and
be willing and able to
comply with the required
tests, treatment instructions
and follow-up visits

ACC/AHA, American College of Cardiology/American Heart Association; ACE-I, angiotensin converting enzyme inhibitor; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; AF, atrial fibrillation; ARB, angiotensin
receptor blocker; ASD, atrial septal defect; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRM, cardiac rhythm management; CRT-D, cardiac resynchronization
therapy-defibrillator; CVA, cerebrovascular accident; ED, emergency department; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; HF, heart failure; HFpEF, heart failure with preserved left ventricular
ejection fraction; HFrEF, heart failure with reduced left ventricular ejection fraction; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LAP, left atrial pressure; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NNT, number needed to treat; NYHA, New York Heart Association functional class; OMT, optimal medical therapy; PAP, pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PCI, percutaneous coronary intervention;
PCWP, pulmonary capillary wedge pressure; PFO, patent foramen ovale; PTCA, percutaneous transluminal angioplasty; RV, right ventricle; SBP, systolic blood pressure; TIA, transient ischemic attack; VAD, ventricular assist device; VT,
ventricular tachycardia; VF, ventricular fibrillation; VSD, ventricular septal defect; WBC, white blood cell count.

Study (citation)

TABLE 3 | Continued
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Clinical Evidence for Ambulatory
Monitoring Implantable Cardiovascular
Devices
As already seen with implantable cardiovascular devices, there is
a wealth of data that can be harnessed through minimally invasive
means and transmitted to a secure data repository via remote
wireless technology. Newer implantable cardiac monitoring
devices for HF oﬀer the ability to provide individualized data
trends and ideally predict clinical events before they occur.
However, isolated device alerts need to be used in conjunction
with other clinical data to avoid overutilization of health care
resources and increased hospitalizations. Successful translation
of remote device based monitoring into successful clinical
management of these patients will require simple prospectively
validated algorithms that indicate how to use raw data from
individual devices to make timely and appropriate changes in
clinical management without overburdening staﬀ. At this time,
despite a wealth of smaller studies evaluating these devices
(Table 3), larger clinical radnomized trials are still necessary
to demonstrate that implantable device based hemodynamic
sensors beneﬁcially impact morbidity and mortality in HF
patients.

Future of Ambulatory Heart Failure
Implantable Cardiovascular Monitoring
Devices
Future directions for remote implantable PAP and LAP devices
are broad. In cardiac patients, one can easily imagine the role for
these devices in better understanding exercise physiology. They
could also aid in clarifying the hemodynamics in particularly
challenging outpatients such as those with diﬃcult to assess
pulmonary pressures by echocardiography (e.g., rheumatic mitral
valve disease, severe pulmonary hypertension, morbidly obese
patients.) Furthermore, in advanced HF patients with known
arrhythmias, there can be a role to assess the clinical impact
of supraventricular arrhythmias such as atrial ﬁbrillation and
ventricular arrhythmias, as well as addressing the question of
whether these rhythm disturbances are causal or secondary to
ADHF. Additionally, with the pressure to avoid indwelling lines,
invasive procedures and overburdening intensive care units, preexisting internal devices that monitor ﬁlling pressures could
facilitate the management of these particularly high risk patients
when admitted for both cardiac and non-cardiac issues, including
perioperative hemodynamic and ﬂuid management.
In advanced HF patients with left ventricular assist devices
(LVAD) who are recurrently admitted with symptoms of
congestion and ﬂuid overload, LAP and PAP monitors may
potentially help to discern elevated left sided ﬁlling pressures

LAP and PAP monitors

from other causes of dyspnea, and volume overload (e.g., chronic
kidney disease progression, hypoalbuminemia, protein-losing
enteropathy). However, further clinical review and evaluation
still may be necessary to exclude a failing right ventricle in
response to LVAD placement and manage other non-cardiac
etiologies for recurrent hospitalizations. These devices may also
be able to detect low ﬁlling pressures in patients with LVADs
who urgently need increased intravascular volume in order
for optimal device function and cardiac output. It remains
to be seen whether regulatory agencies and transplantation
societies will endorse the use of implantable LAP or PAP
monitors as an alternative to indwelling PA catheters in
the pre-heart transplant setting, with the intent to obviate
the need for hospitalization in the intensive care unit and
periodic replacement of PA catheters that are associated with
procedural and other risks including line infection, sepsis, and
thromboembolism.
There are also innumerable non-cardiac scenarios in which
continuous assessment of cardiac hemodynamics and ﬁlling
pressures would be invaluable. A recently published substudy
of the CHAMPION trial found that of the 217 patients who
did not meet criteria for pulmonary hypertension during the
implantation right heart catheterization, 48.8% (N = 16)
met criteria based on continuously observed PAP over the
ﬁrst week post-implantation. This implies that an implantable
heart monitor may assist with improved diagnosis of pulmonary
hypertension and perhaps better guide future trials targeting
pulmonary hypertension (Frantz et al., 2008). It is foreseeable
that future clinical investigations using these hemodynamic
monitors may extend to non-HF patients, especially in eﬀorts
to improve management of volume status in the outpatient
setting, improve patients’ quality of life, and reduce rates of
hospital readmission for hypo- or hypervolemia. Patients with
end stage renal disease, primary pulmonary hypertension or
portal hypertension are patient populations with similar high
healthcare utilization. Renal replacement and diuretic therapies
usually target a patient’s known “dry weight,” which, as discussed
above, is often not an accurate or reliable measure of true volume
status. Furthermore, implantable hemodynamic monitors can
detect other clinically signiﬁcant events, such as poorly tolerated
arrhythmias or hemodynamic shifts, that may be aﬀecting
patients and were previously unappreciated (Braunschweig et al.,
2006).
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